Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterised by progressive weakness and impaired sensory function in the legs and arms. The disorder is sometimes referred to as chronic relapsing polyneuropathy. It is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. It can occur at any age and in both genders, although CIDP is more common in young adults, and in men more so than women.
It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.
Treatment for CIDP includes corticosteroids such as prednisone, which may be prescribed alone or in combination with immunosuppressant drugs. Plasmapheresis (plasma exchange) and intravenous immunoglobulin (IVIg) therapy are effective. IVIg may be used even as a first-line therapy. Physiotherapy may improve muscle strength, function and mobility, and minimize the shrinkage of muscles and tendons and distortions of the joints.
Read more articles on Chronic Inflammatory Demyelinating Polyneuropathy.